Mira Bhaindhar muncipal corporation invites eligible candidates for filling up vacant positions by walk in interview for medical services.
Gilead Sciences, Inc, a biopharmaceutical company, announced detailed 48-week results from two large phase 3 clinical trials (Studies 108 and 110) evaluating once-daily tenofovir alafenamide (TAF) 25 mg in treatment-naïve and treatment-experienced adults with HBeAg-negative and HBeAg-positive chronic hepatitis B virus (HBV) infection. Data were presented this week during two oral sessions (GS06 and GS12) at The International Liver Congress 2016 in Barcelona, Spain.